

# An evidence-based algorithm for the utility of FDG-PET for diagnosing Alzheimer's disease according to presence of medial temporal lobe atrophy

Michael J. Firbank, Jim Lloyd, David Williams, Robert Barber, Sean J. Colloby, Nicky Barnett, Kirsty Olsen, Christopher Davison, Cam Donaldson, Karl Herholz and John T. O'Brien

## Background

Imaging biomarkers for Alzheimer's disease include medial temporal lobe atrophy (MTLA) depicted on computed tomography (CT) or magnetic resonance imaging (MRI) and patterns of reduced metabolism on fluorodeoxyglucose positron emission tomography (FDG-PET).

## Aims

To investigate whether MTLA on head CT predicts the diagnostic usefulness of an additional FDG-PET scan.

## Method

Participants had a clinical diagnosis of Alzheimer's disease ( $n=37$ ) or dementia with Lewy bodies (DLB;  $n=30$ ) or were similarly aged controls ( $n=30$ ). We visually rated MTLA on coronally reconstructed CT scans and, separately and blind to CT ratings, abnormal appearances on FDG-PET scans.

## Results

Using a pre-defined cut-off of MTLA  $\geq 5$  on the Scheltens (0–8) scale, 0/30 controls, 6/30 DLB and 23/30 Alzheimer's disease had marked MTLA. FDG-PET performed well for diagnosing Alzheimer's disease *v.* DLB in the low-MTLA group (sensitivity/specificity of 71%/79%), but in the high-MTLA

group diagnostic performance of FDG-PET was not better than chance.

## Conclusions

In the presence of a high degree of MTLA, the most likely diagnosis is Alzheimer's disease, and an FDG-PET scan will probably not provide significant diagnostic information. However, in cases without MTLA, if the diagnosis is unclear, an FDG-PET scan may provide additional clinically useful diagnostic information.

## Declaration of interest

M.F. reports grants from National Institute for Health Research, K.H. reports grants and personal fees from Lilly/Avid Radiopharmaceuticals, personal fees from GE Healthcare, Cytox and Elan, other from Herholz Consulting GmbH, J.O.B. reports grants and other from GE Healthcare, grants and other from Lilly, other from Bayer Healthcare, other from TauRx, other from Cytox.

## Copyright and usage

© The Royal College of Psychiatrists 2015.

Dementia affects around 35 million people worldwide, with numbers set to double in the next 30 years. Increasingly, dementia is an international governmental priority, with early and accurate assessment and diagnosis placed at the heart of effective management pathways. The two main causes of degenerative dementia in older people are Alzheimer's disease, responsible for about 65% of all cases, and dementia with Lewy bodies (DLB), responsible for 10–15% of cases in older people.

Most international guidelines for assessment and diagnosis of dementia advocate the use of structural imaging (computed tomography (CT) or magnetic resonance imaging (MRI)) as routine, both to exclude other intra-cerebral pathologies and determine the extent of regional brain atrophy.<sup>1–3</sup> Functional imaging methods such as fluorodeoxyglucose positron emission tomography (FDG-PET) and perfusion single-photon emission computed tomography (SPECT) are generally advocated as useful to clarify diagnosis when doubt remains after clinical assessment and structural imaging results.

In the National Institute on Aging's revised diagnostic guidelines<sup>4</sup> proposed for Alzheimer's disease clinical diagnosis, three imaging biomarkers for Alzheimer's disease are proposed: medial temporal lobe atrophy (MTLA) on structural imaging; temporoparietal hypometabolism of FDG-PET; and raised amyloid binding on amyloid-PET. The authors suggest that further research is needed 'to prioritize biomarkers and to determine their value and validity in practice and research settings'. This is important, not only to

enable the appropriate sequencing of biomarkers but also from a health economic and patient perspective to ensure that investigations such as scans are only requested in situations where they will provide useful additional information to inform diagnosis, so that unnecessary cost and inconvenience to patients is minimised.

Modern multi-slice CT scanners allow assessment of MTLA comparable to T1 weighted MRI,<sup>5</sup> and assessment of MTLA with a visual rating scale<sup>6</sup> can be used to help distinguish Alzheimer's disease from DLB.<sup>7</sup> Although there are imaging biomarkers (e.g. FP-CIT, SPECT with FPCIT (dopamine transporter) ligand<sup>8</sup>) which have good diagnostic properties for the specific question of Alzheimer's disease *v.* DLB, the initial clinical picture is frequently unclear, and scans with more general diagnostic ability such as FDG-PET are often requested in the diagnosis of dementia. The aim of this study was thus to investigate the additional diagnostic utility of FDG-PET following visual rating of MTLA on CT using the question of Alzheimer's disease *v.* DLB as an exemplar. We hypothesised that for more severe MTLA, PET would add little further diagnostic information.

## Method

### Participants

Participants were part of a study investigating the relative performance of FDG-PET *vs.* perfusion SPECT in the diagnosis

of Alzheimer's disease and DLB. Main results from the study have been reported elsewhere.<sup>9</sup> The study participants were recruited prospectively from people aged over 60 with mild to moderate dementia (Mini-Mental State Examination score >12) referred to clinical services in north-east England, together with healthy controls of similar age, who were recruited from spouses of participants with dementia ( $n=9$ ), along with those who had previously indicated a willingness to participate in research ( $n=22$ ). Study participants were recruited between June 2010 and June 2012. Control participants had no symptoms of dementia, and patients met criteria for probable Alzheimer's disease<sup>10</sup> or probable DLB.<sup>11</sup> The study was approved by Newcastle and North Tyneside Research Ethics Committee (REF 09/H0906/88), and all participants (or nominated Independent Mental Capacity Advocate where participant lacked capacity) gave informed consent before participating.

Clinical diagnosis was made by consensus between three experienced clinicians. Neither FDG-PET nor the MTLA ratings from CT were used to inform the diagnosis; the only information regarding CT available to the diagnostic raters was from a previous clinical CT report providing information about the extent of any vascular pathology present and confirmation that no space occupying lesion was present. All participants had to have sufficient command of English and adequate visual and auditory acuity to allow cognitive and neuropsychological testing. Exclusion criteria were (1) past history of alcohol or drug dependence; (2) contraindications for FDG-PET scanning (e.g. inability to lie flat); (3) fasting blood glucose level more than 180 mg/dL. All those meeting in/exclusion criteria who consented to take part were included in the study. We recruited 102 individuals, of whom three withdrew before completing both scans, and two were excluded owing to scanner technical problems. A total of 37 people with Alzheimer's disease, 30 with DLB and 30 controls were successfully scanned with FDG-PET-CT.

Participants underwent detailed neuropsychiatric investigation including the Cambridge Cognitive Examination (CAMCOG),<sup>12</sup> and the Rey Auditory Verbal Learning Test (AVLT).<sup>13</sup> The Cornell scale for depression in dementia<sup>14</sup> was used to assess mood, and for dementia participants we performed the Neuropsychiatric Inventory (NPI)<sup>15</sup> and the Clinician Assessment of Fluctuation (CAF) scale.<sup>16</sup> Parkinsonian motor features were assessed in all participants using the motor subsection of the Unified Parkinson's Disease Rating Scale (UPDRS III).<sup>17</sup>

### Scanning

Scans were performed at Newcastle University using a Siemens Biograph-40 Truepoint FDG-PET-CT. CT scans were obtained using the 40 slice CT with 0.6 mm slices, pitch 0.8, 200 mAs, 120 kV, imaging time 12 s. FDG-PET head scans were done over 10 min starting 30 min after i.v. administration of 250 MBq F-18 FDG. Siemens software was used for iterative reconstruction with scatter and attenuation correction based on the CT scan data obtained immediately before the FDG-PET scan.

### Visual rating

The CT scans were viewed and rated separately by different observers to the PET scans. All ratings were performed blind to diagnosis and to the other images from the same individual.

### Computed tomography

All CT scans were reconstructed as 3 mm thick coronal sections oriented perpendicular to the long axis of the hippocampus by the same operator. Visual rating was performed with a standardised scale (Scheltens scale) to rate right and left MTLA

separately.<sup>6</sup> The scale rates atrophy on a 5-point scale (0 = absent, 1 = minimal, 2 = mild, 3 = moderate and 4 = severe) based on the height of the hippocampal formation and the width of the cerebrospinal fluid (CSF) spaces. For the purpose of analysis, the left and right scores were summed to give a combined MTLA score (maximum score 8). All scans were assessed by consensus between two experienced raters (SC and RB) blinded to diagnosis. Figure 1 shows example CT scans.

### Fluorodeoxyglucose positron emission tomography

Visual rating of the scans was performed blind to diagnosis and any clinical information by three imaging specialists (MJF, EDW and JLL) experienced in analysing and reporting nuclear medicine brain scans.

To facilitate consistency in reporting, the imaging features associated with Alzheimer's disease and DLB were set out in a document – key points were (1) reduced uptake in precuneus and lateral parietal lobes in both Alzheimer's disease and DLB; (2) relative preservation of posterior cingulate in DLB; (3) occipital loss more likely in DLB; and (4) reduced uptake in temporal and frontal lobe more likely in Alzheimer's disease.


Each reader independently rated each scan on a 5-point scale for the degree of confidence in overall abnormality typical of dementia. For all scans not considered to be 'definitely normal', the match to Alzheimer's disease or DLB was also rated, again using a 5-point scale. After individual ratings were completed, the imaging team met to compare and review all their ratings and to produce a set of consensus ratings for each scan. Each scan was also given a tripartite consensus classification of normal, Alzheimer's disease or DLB.

### Quantitative analysis

We also performed region of interest (ROI) analysis on the PET scans. Full details are given elsewhere<sup>9</sup> but briefly, the PET scans were normalised to standard space in SPM8 ([www.fil.ion.ucl.ac.uk/spm](http://www.fil.ion.ucl.ac.uk/spm)), and mean intensity within standard ROIs were calculated for each scan. ROIs were taken from the AAL atlas<sup>18</sup> for medial temporal lobe, (hippocampus+parahippocampal gyrus) and medial occipital lobe (calcarine+lingual gyrus).

### Statistics

Demographic and clinical rating data were analysed with SPSS 19.0 (SPSS, Chicago, IL). Continuous variables were compared using independent Student *t*-tests or analysis of variance (ANOVA). Chi-square tests were used to compare categorical data. receiver operating characteristic (ROC) analysis was performed in SPSS. The diagnostic statistics (sensitivity, etc.) were calculated for Alzheimer's disease vs DLB using R (<http://www.r-project.org/> version 2.14.1) on those with a clinical diagnosis of dementia.



**Fig. 1** Computed tomography of dementia with Lewy bodies with (left) high and (right) low medial temporal lobe atrophy (MTLA): MTLA = 8 v. MTLA = 2, respectively. Greater medial temporal atrophy (arrowed) is clearly visible in the left-hand scan.


For visual rating, the PET Alzheimer's disease positive cases were those with consensus visual rating of definitely or probably Alzheimer's disease, and PET Alzheimer's disease negative cases were all other cases (visual rating of normal scan, unclear, probably or definitely DLB). For the ROI analysis, those with a medial temporal/occipital lobe uptake ratio of <0.7 were classed as PET Alzheimer's disease positive, otherwise negative. The diagnostic classification tables from which the statistics were calculated are available in the supplementary material.

**Results**

Table 1 shows the participant demographics. The groups were well matched for age, years of education, sex and duration of dementia. There were no significant differences between Alzheimer's disease and DLB in CAMCOG scores. As expected, the DLB group had more Parkinsonian symptoms as demonstrated by significantly higher scores on the UPDRS, whereas the Alzheimer's disease group had poorer memory performance on the Rey AVLT. The NPI score was not different between groups, but the DLB patients had more fluctuations of consciousness as measured by the CAF.

All of the control participants had an MTLA of <5. Table 2 shows the characteristics of the patients with dementia according to MTLA. Those with a high MTLA score were older than those with a lower score, but there were no other significant differences.

Figure 1 shows typical CT scans, and Fig. 2 shows the MTLA rating scores by group. In our previous examination of MTLA, we found that a cut-off of ≥5 optimally distinguished Alzheimer's disease from DLB and vascular dementia.<sup>7</sup> With this cut-off, none of the control participants, 6/30 DLB, and 23/37 Alzheimer's disease, had marked MTLA. So a high MTLA score was a good test



**Fig. 2** Medial temporal lobe atrophy rating (L+R) for all participants. Horizontal bar shows group means. DLB, dementia with Lewy bodies; MTLA, medial temporal lobe atrophy.

for excluding non-dementia and most DLB cases, with a positive predictive value of 79%, but a lower sensitivity (62%) for detecting all Alzheimer's disease cases.

Table 3 presents the results of the FDG-PET visual rating consensus classification. PET performed generally very well at distinguishing controls from dementia at all levels of MTLA, with

	Control (n = 30)	Alzheimer's disease (n = 37)	DLB (n = 30)	
Age	76.3 (6.6)	75.8 (7.6)	76.5 (5.8)	$F_{2,94} = 0.11, P = 0.9$
Female : Male	10:20	15:22	7:23	$\chi^2 = 2.2, P = 0.3$
Education (years)	11.9 (2.8)	11.5 (2.6)	10.6 (2.3)	$F_{2,94} = 1.97, P = 0.15$
Duration of dementia (months)	–	44.1 (23.2) [12–132]	38.1 (27.3) [9–120]	$t_{65} = 0.97, P = 0.3^*$
MMSE	28.9 (1.1) [26–30]	20.9 (3.7) [15–28]	21.8 (4.2) [14–28]	$t_{65} = -0.95, P = 0.3^*$
CAMCOG	98.4 (4.0)	71.5 (11.7)	72.6 (13.1)	$t_{65} = -0.35, P = 0.7^*$
Rey total	70.3 (12.3)	25.1 (9.6)	33.4 (12.1)	$t_{65} = -3.1, P = 0.002^*$
Cornell	1.8 (1.8)	4.5 (2.8)	8.1 (3.8)	$F_{2,94} = 35.9, P < 0.001$
CAF total	–	1.5 (2.5)	6.0 (4.7)	$t_{64} = -4.7, P < 0.001^*$
NPI total	–	14.8 (14.6)	19.7 (15.6)	$t_{64} = -1.3, P = 0.2^*$
UPDRS III	2.6 (2.7)	3.7 (3.3)	25.5 (11.9)	$F_{2,94} = 104, P < 0.001$
MTLA ≥ 5	0 (0%)	23 (62%)	6 (20%)	$\chi^2 = 32.6; P < 0.001$

\*Alzheimer's disease v. DLB, Student *t*-test.  
Values are mean (SD) [range]; DLB, dementia with Lewy bodies; CAF, Clinician Assessment of Fluctuation; CAMCOG, Cambridge Cognitive Examination; MMSE, Mini-Mental State Examination; MTLA, medial temporal lobe atrophy; NPI, Neuropsychiatric Inventory; UPDRS III, Unified Parkinson's Disease Rating Scale.

	Alzheimer's disease MTLA < 5 (n = 14)	Alzheimer's disease MTLA ≥ 5 (n = 23)		DLB MTLA < 5 (n = 24)	DLB MTLA ≥ 5 (n = 6)	
Age	71.0 (7.1)	78.7 (6.4)	$T = 3.3, P = 0.002$	75.3 (5.4)	81.0 (5.7)	$T = 2.3, P = 0.031$
Female : Male	7:7	8:15	$\chi^2 = 0.8, P = 0.5$	5:19	2:4	$\chi^2 = 0.4, P = 0.6$
Duration of dementia (months)	39.7 (17)	46.7 (26)	$T = 0.9, P = 0.4$	38.0 (26)	38.0 (35)	$T = 0.0, P = 1.0$
MMSE	21.1 (4.2)	20.8 (3.5)	$T = -0.3, P = 0.8$	22.5 (4.0)	19.0 (3.8)	$T = -1.9, P = 0.06$
CAMCOG	74.0 (12)	70.0 (11)	$T = -1.0, P = 0.4$	74.1 (11)	66.5 (19)	$T = -1.3, P = 0.2$
UPDRS III	3.6 (4.1)	3.7 (2.7)	$T = 0.2, P = 0.9$	24.3 (12)	30.0 (11)	$T = 1.0, P = 0.3$

DLB, dementia with Lewy bodies; CAMCOG, Cambridge Cognitive Examination; MMSE, Mini-Mental State Examination; MTLA, medial temporal lobe atrophy; UPDRS III, Unified Parkinson's Disease Rating Scale.

**Table 3** Consensus visual rating from 3 observers of PET scans by different groups and MTLA severity

MTLA	PET visual rating consensus					PET MTL/occipital ROI ratio mean (SD)
	Definite/probable normal	Definite/probable Alzheimer's disease	Unclear Alzheimer's disease v. DLB	Definite/probable DLB		
<i>Alzheimer's disease</i>						
0–4	14	1 (7%)	10 (71%)*	3 (21%)	0	0.647 (0.032)
5–8	23	1 (4%)	12 (52%)*	6 (26%)	4 (17%)	0.631 (0.069)
<i>DLB</i>						
0–4	24	4 (17%)	5 (21%)	1 (4%)	14 (58%)*	0.751 (0.080)
5–8	6	0	1 (17%)	3 (50%)	2 (33%)*	0.711 (0.123)
<i>Controls</i>						
0–4	30	24 (80%)*	1 (3%)	3 (10%)	2 (7%)	0.681 (0.039)
5–8	0					

\*Correct diagnoses. Ratio of FDG-PET uptake in medial temporal lobe to occipital lobe ROIs also shown. DLB, dementia with Lewy bodies; PET, positron emission tomography; MTL, medial temporal lobe; MTLA, medial temporal lobe atrophy.

24/30 (80%) of control scans being classed as normal and 61/67 (91%) of dementia cases as abnormal. For cases with MTLA <5, visual rating of PET had a sensitivity/specificity of 71%/79% for diagnosis of Alzheimer's disease vs DLB (Table 4). However, for those subjects with a MTLA ≥5, visual inspection of PET performed poorly for distinguishing Alzheimer's disease from DLB, with a sensitivity of 52%.

Table 5 presents ROC analysis of Alzheimer's disease vs DLB for both the visual rating (5-point scale) and the ratio of uptake in the medial temporal to occipital lobe, which we found to have good distinguishing ability in the whole cohort.<sup>9</sup> Visual rating and ROI analysis had similar values of AUC in both low- and high-MTLA groups. For the high-MTLA group, the AUC was 0.69 for visual rating and 0.72 for ROI analysis, neither of which were significantly greater than chance ( $P > 0.1$ ). For low MTLA, both the visual rating and ROI analysis were significant ( $P < 0.001$ ) with AUC of 0.83 for visual rating, indicating good diagnostic ability. One factor influencing the less good diagnostic performance of PET at high MTLA is the increased variability, seen as higher s.d. for the AUC in the ROC analysis, and the ratio of MTLA/occipital lobe FDG uptake (Table 3), where the variance is higher in the MTLA ≥5 group, significantly so in Alzheimer's disease (s.d. = 0.069 vs 0.032,  $F_{22,13} = 0.22$ ,  $P = 0.006$ ).

## Discussion

Using a predetermined cut-off of ≥5 on the MTLA visual rating scale on 3 mm slice CT for diagnosing Alzheimer's disease (compared to DLB), we found a sensitivity of 62% and a specificity of 80%. The cut-off also excluded all of the normal control participants and had good positive predictive value for Alzheimer's

disease (79%). Analysis of PET scans in the high-MTLA group did not significantly improve diagnostic discrimination. In the group with low MTLA (14 Alzheimer's disease, 23 DLB), PET performed well for identifying controls, and also had a sensitivity and specificity of 71% and 79% for distinguishing Alzheimer's disease from DLB.

Visual rating of the hippocampus can be performed fairly quickly by a trained person, with good reliability, and studies have shown it to be comparable to volumetric measurement for assessment of the hippocampus in Alzheimer's disease.<sup>19</sup> CT scans are quick and relatively cheap to perform, and are frequently done for suspected dementia to exclude space occupying lesions or vascular disease. Alternatively, if coronal MRI head scans are available, MTLA could be rated from those. We suggest that rating of MTLA should form a standard part of the examination report, since our data suggest that when there is a high degree of MTLA present, then the most likely diagnosis is Alzheimer's disease, and it is unlikely that an FDG-PET scan will provide significant additional diagnostic information. In cases where MTLA is absent or mild, and the diagnosis is unclear, then an FDG-PET scan may provide additional information. Our results are consistent with those of Ossenkoppole *et al*<sup>20</sup> who found that PET imaging contributed most to diagnosis when there was greater diagnostic uncertainty before considering the scan results. In the case where Alzheimer's disease is still suspected, but there is absent MTLA, testing levels of Aβ42 in CSF may be appropriate, as this has good sensitivity for detecting Alzheimer's disease.<sup>21</sup>

Reduction in FDG uptake in the posterior cingulate cortex (PCC) is one of the characteristic features of Alzheimer's disease. Previous work has shown that this is associated with disconnection between the PCC and the medial temporal lobe.<sup>22,23</sup> It is thus likely that the presence of severe MTLA on a CT scan will be accompanied

**Table 4** Diagnostic statistics for identifying Alzheimer's disease (vs DLB)

	Sensitivity	Specificity	Positive predictive value	Negative predictive value	Accuracy	Likelihood ratio for positive result
CT rating	0.62 (0.45–0.77)	0.80 (0.61–0.92)	0.79 (0.60–0.91)	0.63 (0.46–0.78)	0.70 (0.58–0.80)	3.11 (1.46–6.64)
PET visual rating, all cases	0.59 (0.42–0.75)	0.80 (0.61–0.92)	0.79 (0.59–0.91)	0.62 (0.45–0.76)	0.69 (0.56–0.79)	2.97 (1.39–6.38)
CT <5, PET visual rating	0.71 (0.42–0.90)	0.79 (0.57–0.92)	0.67 (0.39–0.87)	0.83 (0.60–0.94)	0.76 (0.59–0.88)	3.43 (1.47–8.00)
CT ≥5, PET visual rating	0.52 (0.31–0.73)	0.83 (0.36–0.99)	0.92 (0.62–1.00)	0.31 (0.12–0.59)	0.59 (0.39–0.76)	3.13 (0.50–19.5)
CT & PET visual rating	0.89 (0.74–0.96)	0.63 (0.44–0.79)	0.75 (0.59–0.86)	0.83 (0.60–0.94)	0.78 (0.65–0.87)	2.43 (1.50–3.94)
PET MTL/Occipital ROI	0.89 (0.74–0.96)	0.80 (0.61–0.92)	0.85 (0.69–0.94)	0.86 (0.66–0.95)	0.85 (0.74–0.92)	4.46 (2.16–9.20)
CT <5, PET ROI	0.93 (0.64–1.00)	0.83 (0.62–0.95)	0.76 (0.50–0.92)	0.95 (0.74–1.00)	0.87 (0.71–0.95)	5.57 (2.25–13.8)
CT ≥5, PET ROI	0.87 (0.65–0.97)	0.67 (0.24–0.94)	0.91 (0.69–0.98)	0.57 (0.2–0.88)	0.83 (0.64–0.93)	2.61 (0.83–8.18)
CT & PET ROI	0.97 (0.84–1.00)	0.67 (0.47–0.82)	0.78 (0.63–0.89)	0.95 (0.74–1.00)	0.84 (0.72–0.91)	2.92 (1.75–4.86)

95% confidence interval in brackets. PET ROI is the MTL/occipital uptake ratio. The CT & PET visual rating figures are obtained by following the diagnostic flowchart in Fig. 3, i.e. an Alzheimer's disease diagnosis is given via either MTLA on CT, or Alzheimer's disease positive FDG-PET scan following normal MTL on CT. CT, computed tomography; DLB, dementia with Lewy bodies; MTL, medial temporal lobe; MTLA, medial temporal lobe atrophy; PET, positron emission tomography; ROI, region of interest.

**Table 5** Values from receiver operating characteristic analysis based on the consensus rating and the ratio of ROI in the occipital/medial temporal lobe

MTL rating	PET Alzheimer's disease v. DLB consensus visual rating (n = 67)	PET ROI MTL/occipital (n = 67)
	AUC (s.e.)	AUC (s.e.)
0–4	0.83 (0.07)***	0.85 (0.07)***
5–8	0.69 (0.13)	0.72 (0.15)

Values denote sensitivity/specificity for identifying Alzheimer's disease.  
\*\*\* $P < 0.001$ . AUC, area under the curve; DLB, dementia with Lewy bodies; MTL, medial temporal lobe; PET, positron emission tomography; ROI, region of interest.


by Alzheimer-like features on the FDG-PET scan due to this disconnection. This partly explains the relative lack of additional diagnostic information from FDG-PET in high MTLA. In the case of uncertain diagnosis in those with high MTLA, then a PET/SPECT scan examining a different neural system may be more useful (e.g. with an FP-CIT SPECT scan for detecting dopaminergic deficit associated with DLB<sup>8</sup>).

Participants with high MTLA were older. Even in healthy individuals, MTLA tends to increase with age,<sup>24</sup> there is an age-related decrease in FDG-PET uptake,<sup>25</sup> and subjects with later onset Alzheimer's disease have previously been reported to have less pronounced FDG deficits.<sup>26</sup> The poorer diagnostic performance of FDG-PET in the high MTLA may thus have been in part due to lower and less distinct FDG uptake patterns in older subjects. It is also possible that the DLB patients with high MTLA may have had some degree of Alzheimer's disease pathology present.

Caveats are that we only investigated Alzheimer's disease and DLB in this study. Evaluation of MTLA in cases of mild cognitive impairment has good predictive value for development of Alzheimer's disease<sup>27</sup> and studies are needed as to how best to combine this with other biomarkers such as PET. Patients with fronto-temporal dementia commonly have hippocampal atrophy, and it is difficult to differentiate FTD from Alzheimer's disease on the basis of MTLA.<sup>28–30</sup> In the case of suspected FTD, more detailed examination of structural scans may help the diagnosis, since the pattern of structural atrophy is different to that seen in Alzheimer's disease.<sup>31,32</sup> On FDG-PET scans, patients with FTD typically have greater frontal and temporal hypometabolism than Alzheimer's disease,<sup>33</sup> and studies have found generally good diagnostic differential ability for Alzheimer's disease vs FTD<sup>33–35</sup> though with, in general, lower reported sensitivity (53–72%) for FTD than specificity (95–99%).

We have previously shown that MTLA also discriminates Alzheimer's disease from vascular dementia,<sup>7</sup> and other studies have also found MTLA in vascular dementia to be intermediate between controls and Alzheimer's disease<sup>36,37</sup> and hence the higher the MTLA score, the less likely there is vascular dementia. Examination of MRI scans for presence of vascular lesions is most likely to be of use to identify/exclude cases of vascular dementia.<sup>38</sup>

We recruited control participants from a similar demographic to the dementia participants. Controls had the highest mean years of education of any group, but there were no significant differences between the groups in age, sex or years of education. Our diagnosis was based on clinical assessment, without the aid of neuroimaging or CSF biomarkers, an approach which has been validated in our group both against autopsy and other imaging markers and is a standard now accepted by regulatory authorities.<sup>8</sup> Although there may be some mistaken clinical diagnoses, we believe that they are unlikely to affect our main conclusion that a FDG-PET scan will probably not help the diagnosis of Alzheimer's disease in the presence of MTLA on CT.

**Fig. 3** Evidence-based imaging algorithm for FDG-PET use.

DLB, dementia with Lewy bodies; FTD, fronto-temporal dementia; FP-CIT, single-photon emission computed tomography with FP-CIT (dopamine transporter) ligand; CT, computed tomography; FDG-PET, fluorodeoxyglucose positron emission tomography; VaD, vascular dementia; Aβ, amyloid-beta; CSF, cerebrospinal fluid.

Many countries, including the UK, have initiatives aimed at raising the profile of dementia and increasing the numbers diagnosed, with some research estimating that currently less than half the people with dementia receive a formal diagnosis.<sup>39</sup> There will also be a substantial increase in the numbers of patients with dementia over the next 40 years, due to increases in lifespan.<sup>40</sup> Neuroimaging services will be an important part of providing diagnoses to these increasing numbers. However, FDG-PET remains a relatively expensive option and involves a rather lengthy procedure for the patient compared to a CT scan. Therefore, to maximise health care resources, and minimise unnecessary investigations for people with dementia, FDG-PET will have to be used only as part of an evidence based diagnostic pathway. Based on our results, a suggested algorithm for considering neuroimaging, dependent on both the CT results and the clinical question, is presented in Fig. 3. Future work should seek to incorporate other imaging biomarkers into this algorithm, for example, amyloid-PET.

### Funding

Funded by the National Institute for Health Research, NIHR Biomedical Research Centre and Lewy-body Dementia Biomedical Research Unit awarded to Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, and the NIHR Biomedical Research Centre and Biomedical Research Unit in Dementia awarded to the Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge.

### Acknowledgements

We thank the Dementia and Neurodegenerative Diseases Research Network (DeNDroN) for valuable support with clinical recruitment. This article presents independent research funded by the National Institute for Health Research (NIHR) under its Research for Patient Benefit (RfPB) Programme (grant reference number PB-PG-1207-131-05). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

**Michael J. Firbank**, PhD, Institute of Neuroscience, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne and Nuclear Medicine Department, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne;  
**Jim Lloyd**, PhD, Nuclear Medicine Department, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne; **David Williams**, PhD, **Robert Barber**, MD, **Sean J. Colloby**, PhD, **Nicky Barnett**, BSc, **Kirsty Olsen**, BSc, **Christopher Davison**, MRCPsych, Institute for Neuroscience, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne; **Cam Donaldson**, PhD, Institute of Health and Society, Newcastle University, Newcastle upon Tyne and Yunus Centre, Glasgow Caledonian University, Glasgow; **Karl Herholz**, PhD, Wolfson Molecular Imaging Centre, Institute of Brain, Behaviours and Mental Health, University of Manchester, Manchester; **John T. O'Brien**, DM, Department of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge and Institute for Neuroscience, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK

**Correspondence:** Dr Michael J. Firbank, Institute of Neuroscience and Newcastle University Institute for Ageing, Campus for Ageing and Vitality, Newcastle upon Tyne NE4 5PL, UK. Email: michael.firbank@ncl.ac.uk

First received 21 Nov 2014, accepted 7 Dec 2014

## References

- Hort J, O'Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. *Eur J Neurol* 2010; **17**: 1236–48.
- Jack CR, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 2011; **7**: 257–62.
- N.I.C.E. Dementia. Supporting people with dementia and their carers in health and social care. <http://www.nice.org.uk/cg42> Accessed on: 17/10/2013
- McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 2011; **7**: 263–9.
- Wattjes MP, Henneman WJP, van der Flier WM, de Vries O, Träber F, Geurts JGG, et al. Diagnostic imaging of patients in a memory clinic: comparison of MR imaging and 64-detector row CT. *Radiology* 2009; **253**: 174–83.
- Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. *J Neurol Neurosurg Psychiatry* 1992; **55**: 967–72.
- Burton EJ, Barber R, Mukaeova-Ladinska EB, Robson J, Perry RH, Jaros E, et al. Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. *Brain* 2009; **132**: 195–203.
- McKeith I, O'Brien J, Walker Z, Tatsch K, Booi J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with I-123-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. *Lancet Neurol* 2007; **6**: 305–13.
- O'Brien JT, Firbank MJ, Davison C, Barnett N, Bamford C, Donaldson C, et al. FDG-PET and perfusion SPECT in the diagnosis of Alzheimer's disease and Lewy body dementias. *J Nucl Med* 2014; **55**: 1959–65.
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. *Neurology* 1984; **34**: 939–44.
- McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. *Neurology* 2005; **65**: 1863–72.
- Roth M, Huppert FA, Mountjoy CQ, Tym E. *CAMDEX-R: Revised Cambridge Examination for Mental Disorders of the Elderly*. Cambridge University Press, 1999.
- Schmidt M. *Rey Auditory Verbal Learning Test: A Handbook*. Western Psychological Services, 1996.
- Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell scale for depression in dementia. *Biol Psychiatry* 1988; **23**: 271–84.
- Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. *Neurology* 1994; **44**: 2308–14.
- Walker MP, Ayre GA, Cummings JL, Wesnes K, McKeith IG, O'Brien JT, et al. The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia. *Br J Psychiatry* 2000; **177**: 252–6.
- Fahn S, Elton R, Members of the UPDRS development committee. Unified Parkinson's disease rating scale. In *Recent Developments in Parkinson's Disease* (eds S Fahn, CD Marsden, DB Calne, et al.): 153–163, 293–304. MacMillan Healthcare Information, 1987.
- Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. *NeuroImage* 2002; **15**: 273–89.
- Boutet C, Chupin M, Colliot O, Sarazin M, Mutlu G, Drier A, et al. Is radiological evaluation as good as computer-based volumetry to assess hippocampal atrophy in Alzheimer's disease? *Neuroradiology* 2012; **54**: 1321–30.
- Ossenkuppe R, Prins ND, Pijnenburg YAL, Lemstra AW, van der Flier WM, Adriaanse SF, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. *Alzheimers Dement* 2013; **9**: 414–21.
- Ferreira D, Perestelo-Perez L, Westman E, Wahlund LO, Sarria A, Serrano-Aguilar P. Meta-review of CSF core biomarkers in Alzheimer's disease: the state-of-the-art after the new revised diagnostic criteria. *Front Aging Neurosci* 2014; **6**: 47.
- Bozoki AC, Korolev IO, Davis NC, Hoisington LA, Berger KL. Disruption of limbic white matter pathways in mild cognitive impairment and Alzheimer's disease: a DTI/FDG-PET. *Hum Brain Mapp* 2012; **33**: 1792–802.
- Villain N, Desgranges B, Viader F, de la Sayette V, Mézenge F, Landeau B, et al. Relationship between hippocampal atrophy, white matter disruption, and gray matter hypometabolism in Alzheimer's disease. *J Neurosci* 2008; **28**: 6174–81.
- Fjell AM, McEvoy L, Holland D, Dale AM, Walhovd KB. Brain changes in older adults at very low risk for Alzheimer's disease. *J Neurosci* 2013; **33**: 8237–42.
- Chételat G, Landeau B, Salmon E, Yakushev I, Ali Bahri M, Mézenge F, et al. Relationships between brain metabolism decrease in normal aging and changes in structural and functional connectivity. *NeuroImage* 2013; **76**: 167–77.
- Dukart J, Mueller K, Villringer A, Kherif F, Draganski B, Frackowiak R, et al. Relationship between imaging biomarkers, age, progression and symptom severity in Alzheimer's disease. *NeuroImage: Clinical* 2013; **3**: 84–94.
- Clerx L, van Rossum IA, Burns L, Knol DL, Scheltens P, Verhey F, et al. Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment. *Neurobiol Aging* 2013; **34**: 2003–13.
- Muñoz-Ruiz MÁ, Hartikainen P, Koikkalainen J, Wolz R, Julkunen V, Niskanen E, et al. Structural MRI in frontotemporal dementia: comparisons between hippocampal volumetry, tensor-based morphometry, and voxel based morphometry. *PLoS One* 2013; **7**: e52531.
- Galton CJ, Gomez-Anson B, Antoun N, Scheltens P, Patterson K, Graves M, et al. Temporal lobe rating scale: application to Alzheimer's disease and frontotemporal dementia. *J Neurol Neurosurg Psychiatry* 2001; **70**: 165–73.
- de Souza LC, Chupin M, Bertoux M, Lehericy S, Dubois B, Lamari F, et al. Is hippocampal volume a good marker to differentiate Alzheimer's disease from frontotemporal dementia? *J Alzheimer's Dis* 2013; **36**: 57–66.
- Boccardi M, Laakso MP, Bresciani L, Galluzzi S, Geroldi C, Beltramello A, et al. The MRI pattern of frontal and temporal brain atrophy in fronto-temporal dementia. *Neurobiol Aging* 2003; **24**: 95–103.
- Agosta F, Canu E, Sarro L, Comi G, Filippi M. Neuroimaging findings in fronto-temporal lobar degeneration spectrum of disorders. *Cortex* 2012; **48**: 389–413.
- Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. *J Nucl Med* 2008; **49**: 390–8.
- Panegyres PK, Rogers JM, McCarthy M, Campbell A, Wu JS. Fluorodeoxyglucose positron emission tomography in the differential diagnosis of early-onset dementia: a prospective, community-based study. *BMC Neurol* 2009; **9**: 41.
- Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, Barbas NR, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. *Brain* 2007; **130**: 2616–35.
- Dolek N, Saylisoy S, Ozbabalik D, Adapinar B. Comparison of hippocampal volume measured using magnetic resonance imaging in Alzheimer's disease, vascular dementia, mild cognitive impairment and pseudodementia. *J Int Med Res* 2012; **40**: 717–25.
- Van de Pol L, Gertz HJ, Scheltens P, Wolf H. Hippocampal atrophy in subcortical vascular dementia. *Neurodegener Dis* 2011; **8**: 465–9.
- Bhogal P, Mahoney C, Graeme-Baker S, Roy A, Shah S, Fraioli F, et al. The common dementias: a pictorial review. *Eur Radiol* 2013; **23**: 3405–17.
- Connolly A, Gaehl E, Martin H, Morris J, Purandare N. Underdiagnosis of dementia in primary care: variations in the observed prevalence and comparisons to the expected prevalence. *Aging Ment Health* 2011; **15**: 978–84.
- Alzheimer's Society. *Dementia 2013 infographic*. <http://www.alzheimers.org.uk/infographic> (Accessed on: 17/11/2013).